Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SDCBP | O00560 | 3/20 | 0.39 |
| ▸ | SDC2 | P34741 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7674304 | 0.91 | MAPT (0.42) | MAPTALOX15SMN1; SMN2KDM4ESDCBP | |
| SCHEMBL7674481 | 0.91 | MAPT (0.39) | MAPTALOX15SMN1; SMN2KDM4ESDCBP | |
| SCHEMBL7678468 | 0.88 | KDM4E (0.49) | MAPTALOX15SMN1; SMN2KDM4ESDCBP | |
| SCHEMBL7680581 | 0.84 | ALOX15 (0.45) | MAPTALOX15SMN1; SMN2KDM4ESDCBP | |
| SCHEMBL7677127 | 0.84 | MAPT (0.46) | MAPTALOX15SMN1; SMN2KDM4ESDCBP | |
| SCHEMBL7680451 | 0.82 | ALOX15 (0.45) | MAPTALOX15SMN1; SMN2KDM4ESDCBP | |
| SCHEMBL7676186 | 0.81 | ALOX15 (0.44) | MAPTALOX15SMN1; SMN2KDM4ESDCBP | |
| SCHEMBL7677830 | 0.81 | KDM4E (0.41) | MAPTALOX15SMN1; SMN2KDM4ESDCBP | |
| SCHEMBL7677588 | 0.81 | ALOX15 (0.46) | MAPTALOX15SMN1; SMN2KDM4ESDCBP | |
| SCHEMBL7679921 | 0.80 | ALOX15 (0.43) | MAPTALOX15SMN1; SMN2KDM4ESDCBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6380239-B1 | FOR THERAPY OF ARTHRITIS, RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, REPERFUSION INJURY, INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, ULCERATIVE COLITIS, SYSTEMIC LUPUS ERYTHREMATOSIS, SCLERODERMA, APHTHOUS ULCERS, ASTHMA | CELGENE CORPORATION | 2002-04-30 | — | — | US | disclosed |
| CN-1342146-A | Substituted 1-oxo-and 1, 3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels | CELGENE CORP (US) | 2002-03-27 | — | — | CN | disclosed |
| EP-1163219-A1 | SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATORY CYTOKINE LEVELS | CELGENE CORPORATION (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055134-A1 | SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATORY CYTOKINE LEVELS | CELGENE CORPORATION (US) | 2000-09-21 | — | — | WO | disclosed |